WO2023192161A3 - Methods and compositions for attenuating immune response associated with rna therapeutics - Google Patents
Methods and compositions for attenuating immune response associated with rna therapeutics Download PDFInfo
- Publication number
- WO2023192161A3 WO2023192161A3 PCT/US2023/016383 US2023016383W WO2023192161A3 WO 2023192161 A3 WO2023192161 A3 WO 2023192161A3 US 2023016383 W US2023016383 W US 2023016383W WO 2023192161 A3 WO2023192161 A3 WO 2023192161A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- administration
- hmo
- methods
- compositions
- immune response
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title 1
- 230000028993 immune response Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 abstract 6
- 210000004251 human milk Anatomy 0.000 abstract 2
- 235000020256 human milk Nutrition 0.000 abstract 2
- 229920001542 oligosaccharide Polymers 0.000 abstract 2
- 150000002482 oligosaccharides Chemical class 0.000 abstract 2
- 238000011260 co-administration Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000000638 stimulation Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
Abstract
Described are methods of attenuating RNA therapeutic-associated immune stimulation comprising co-administering to a subject in need thereof an effective amount of a human milk oligosaccharide (HMO) with the RNA therapeutic. The co-administration includes administration of the HMO before administration of the RNA therapeutic, administration of the HMO concurrently with the RNA therapeutic, administration of the HMO after administration of the RNA therapeutic, or a combination of any of thereof. Also described are pharmaceutical compositions comprising an RNA therapeutic and a human milk oligosaccharide (HMO).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263324238P | 2022-03-28 | 2022-03-28 | |
| US63/324,238 | 2022-03-28 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2023192161A2 WO2023192161A2 (en) | 2023-10-05 |
| WO2023192161A3 true WO2023192161A3 (en) | 2023-11-09 |
Family
ID=88203139
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2023/016383 WO2023192161A2 (en) | 2022-03-28 | 2023-03-27 | Methods and compositions for attenuating immune response associated with rna therapeutics |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2023192161A2 (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120093874A1 (en) * | 2009-07-14 | 2012-04-19 | Morinaga Milk Industry Co., Ltd. | Method for screening for diet providing production of milk having immunoregulatory action |
| US20200249244A1 (en) * | 2017-10-06 | 2020-08-06 | Prothena Biosciences Limited | Methods of detecting transthyretin |
| US20210038732A1 (en) * | 2018-02-12 | 2021-02-11 | Interna Technologies B.V. | Anticancer microrna and lipid formulations thereof |
| WO2021030617A2 (en) * | 2019-08-13 | 2021-02-18 | Amyris, Inc. | Improved oligosaccharide production in yeast |
-
2023
- 2023-03-27 WO PCT/US2023/016383 patent/WO2023192161A2/en unknown
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120093874A1 (en) * | 2009-07-14 | 2012-04-19 | Morinaga Milk Industry Co., Ltd. | Method for screening for diet providing production of milk having immunoregulatory action |
| US20200249244A1 (en) * | 2017-10-06 | 2020-08-06 | Prothena Biosciences Limited | Methods of detecting transthyretin |
| US20210038732A1 (en) * | 2018-02-12 | 2021-02-11 | Interna Technologies B.V. | Anticancer microrna and lipid formulations thereof |
| WO2021030617A2 (en) * | 2019-08-13 | 2021-02-18 | Amyris, Inc. | Improved oligosaccharide production in yeast |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023192161A2 (en) | 2023-10-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2005094799A3 (en) | Use of an nmda receptor antagonist for the treatment of tinnitus induced by cochlear excitotoxicity | |
| DE69030880D1 (en) | Composition for stimulating the immune system | |
| Morikawa et al. | Possible participation of tumoricidal macrophages in the therapeutic effect of bleomycin on a transplantable rat fibrosarcoma | |
| JP2017533972A5 (en) | ||
| Danesh et al. | Apremilast and adalimumab: a novel combination therapy for recalcitrant psoriasis | |
| JP2005538190A5 (en) | ||
| US20190328802A1 (en) | Compositions and methods for common colds | |
| Paterson et al. | A randomized, double-blind, placebo-controlled, sequential parallel study of CERC-301 in the adjunctive treatment of subjects with severe depression and recent active suicidal ideation despite antidepressant treatment | |
| JP2016505050A5 (en) | ||
| Dupuy et al. | Intralesional interferon-α and zidovudine in epidemic Kaposi's sarcoma | |
| WO2023192161A3 (en) | Methods and compositions for attenuating immune response associated with rna therapeutics | |
| WO2005009217A3 (en) | Diagnosis of pre-cancerous conditions using pcdgf agents | |
| JP2000507234A (en) | Intranasal administration of treatment for delayed onset vomiting | |
| Brausch et al. | The treatment of tuberculosis | |
| Adamczyk et al. | A 12-year old girl with severe plaque psoriasis and Down syndrome treated successfuly with etanercept | |
| Noguchi et al. | Case report. Sporotrichosis successfully treated with itraconazole in Japan | |
| EP3639836B1 (en) | Composition comprising isoferulic acid for use in the treatment of autoimmune hepatitis | |
| Ito et al. | Cyclophosphamide followed by mizoribine as maintenance therapy against refractory steroid-dependent nephrotic syndrome | |
| Sharma et al. | Mucormycosis-a Fungal Infection in Patient Recovered from COVID-19 | |
| Cummins et al. | Sorafenib priming may augment salvage chemotherapy in relapsed and refractory FLT3-ITD-positive acute myeloid leukemia | |
| EP3538159B1 (en) | Inhibition of fibrosis in non-alcoholic fatty liver disease patients | |
| Fried et al. | A RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF ORAL SILYMARIN (MILK THISTLE) FOR CHRONIC HEPATITIS C: FINAL RESULTS OF THE SYNCH MULTICENTER STUDY: 228 | |
| Chipps et al. | Omalizumab significantly improves quality of life in patients with severe persistent asthma | |
| JP4221267B2 (en) | Drugs to suppress itching | |
| Hossain et al. | Use of Human Granulocyte Colony-Stimulating Factor (G-CSF) in Consolidation Chemotherapy in Adult Acute Myeloid Leukaemia (AML) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23781619 Country of ref document: EP Kind code of ref document: A2 |